NUZ — Neurizon Therapeutics Share Price
0.000.00%
Last trade - 00:00- AU$59.08m
- AU$48.96m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.96 | ||
| Price to Tang. Book | 4.96 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 33.55 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -122.39% | ||
| Return on Equity | -150.5% | ||
| Operating Margin | -827.77% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 4.12 | 3.67 | 4.51 | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Neurizon Therapeutics Ltd, formerly PharmAust Limited, is an Australia-based clinical-stage biotechnology company. The Company is engaged in advancing treatments for neurodegenerative diseases. The Company is focused on developing its lead drug candidate, NUZ-001, for the treatment of Amyotrophic Lateral Sclerosis (ALS), which is the common form of motor neuron disease. ALS is a devastating neurodegenerative condition that primarily affects nerve cells that control voluntary muscles.
Directors
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 3rd, 2000
- Public Since
- October 5th, 2001
- No. of Shareholders
- 4,007
- No. of Employees
- 52
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 492,305,766
- Address
- 96-100 Albert Road, Level 4, SOUTH MELBOURNE, 3205
- Web
- https://www.neurizon.com/
- Phone
- +61 396927222
- Auditors
- RSM Australia Partners
Upcoming Events for NUZ
Q3 2025 Neurizon Therapeutics Ltd Activities Report Presentation
Full Year 2025 Pharmaust Ltd Earnings Release
PharmAust Ltd Annual Shareholders Meeting
Similar to NUZ
Acrux
Australian Stock Exchange - SEATS
AFT Pharmaceuticals
Australian Stock Exchange - SEATS
Althea group
Australian Stock Exchange - SEATS
Anatara Lifesciences
Australian Stock Exchange - SEATS
Argent BioPharma
Australian Stock Exchange - SEATS
FAQ
What is the Neurizon Therapeutics share price?
As of Today at 04:13 UTC, shares in Neurizon Therapeutics are trading at AU$0.12. This share price information is delayed by 15 minutes.
How has the Neurizon Therapeutics share price performed this year?
Shares in Neurizon Therapeutics last closed at AU$0.12 and the price had moved by -52% over the past 365 days. In terms of relative price strength the Neurizon Therapeutics share price has underperformed the ASX All Ordinaries Index by -53.98% over the past year.
What are the analyst and broker recommendations for Neurizon Therapeutics?
The overall consensus recommendation for Neurizon Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Neurizon Therapeutics dividend yield?
Neurizon Therapeutics does not currently pay a dividend.
Does Neurizon Therapeutics pay a dividend?
Neurizon Therapeutics does not currently pay a dividend.
When does Neurizon Therapeutics next pay dividends?
Neurizon Therapeutics does not currently pay a dividend.
How do I buy Neurizon Therapeutics shares?
To buy shares in Neurizon Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Neurizon Therapeutics?
As of the previous close price of AU$0.12, shares in Neurizon Therapeutics had a market capitalisation of AU$59.08m.
Where are Neurizon Therapeutics shares listed?
Here are the trading details for Neurizon Therapeutics:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: NUZ
What kind of share is Neurizon Therapeutics?
Based on an overall assessment of its quality, value and momentum Neurizon Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Neurizon Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Neurizon Therapeutics is AU$0.42. That is 250% above the last closing price of AU$0.12.
Analysts covering Neurizon Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreWhat is the trend in the Neurizon Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Neurizon Therapeutics. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -40.74%.
As of the last closing price of AU$0.12, shares in Neurizon Therapeutics were trading -27.35% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Neurizon Therapeutics PE Ratio?
The Neurizon Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.12.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Neurizon Therapeutics?
Neurizon Therapeutics' management team is headed by:
- Martine Keenan - CEO
- Robert Bishop - EDR
- John Horton - OTH
- Colette Sims - OTH
- Sam Wright - SEC
- Neville Bassett - NED